Seminari di Ematologia Oncologica - Società Italiana di Ematologia

Chen HT, McBride KM, et al. Role of genomic instability
and p53 in AID-induced c-myc-Igh translocations.
Nature. 2006; 440: 105-109.
30. Franco S, Gostissa M, Zha S, Lombard DB, Murphy
MM, Zarrin AA, et al. H2AX prevents DNA breaks from
progressing to chromosome breaks and translocations.
Mol Cell. 2006; 21: 201-214.
31. Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W,
Wright GW, et al. Aberrant immunoglobulin class switch
recombination and switch translocations in activated
B cell-like diffuse large B cell lymphoma. J Exp Med.
2007; 204: 633-643.
32. Robbiani DF, Bothmer A, Callen E, Reina-San-Martin
B, Dorsett Y, Difilippantonio S, et al. AID is required for
the chromosomal breaks in c-myc that lead to cmyc/IgH
translocations. Cell. 2008; 135: 1028-1038.
33. Callén E, Jankovic M, Difilippantonio S, Daniel JA, Chen
HT, Celeste A, et al. ATM prevents the persistence and
propagation of chromosome breaks in lymphocytes.
Cell. 2007; 130: 63-75.
34. Pasqualucci L, Dominguez-Sola D, Chiarenza A,
Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations
of acetyltransferase genes in B-cell lymphoma.
Nature. 2011; 471: 189-95.
35. Colomo L, Lopez-Guillermo A, Perales M, Rives S,
Martınez A, Bosch F, et al. Clinical impact of the differentiation
profile assessed by immunophenotyping
in patients with diffuse large B-cell lymphoma. Blood.
2003; 101: 78-84.
36. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD,
Delabie J, Ott G, et al. Confirmarion of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray.
Blood. 2004; 103: 275-282.
37. Xiao C, Srinivasan L, Calado DP, Patterson HC,
Zhang B, Wang J, et al. Lymphoproliferative disease
and autoimmunity in mice with increate miR-17-92
expression in lymphocytes. Nat Immunol. 2008; 9:
405-414.
38. Morin RD, Johnson NA, Severson TM, Mungall AJ,
An J, Goya R, et al. Somatic mutations altering EZH2
(Tyr641) in follicular and diffuse large B-cell lymphomas
of germinal-center origin. Nat Genet. 2010;
42: 181-185.
39. Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S,
Ohshima K, et al. Comparison of genome profiles for
identification of distinct subgroups of diffuse large Bcell
lymphoma. Blood. 2005; 106: 1770-1777.
40. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright
GW et al. Oncogenic CARD11 mutations in human diffuse
large B-cell lymphoma. Science. 2008; 319: 1676-
1679.
41. Compagno M, Lim WK, Grunn A, Nandula SV,
Brahmachary M, Shen Q, et al. Mutations of multiple
genes cause deregulation of NF-kappaB in large B-celllymphoma.
Nature. 2009; 459: 717-721.
42. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi
Meccanismi patogenetici
K, et al. Frequent inactivation of A20 in B-cell lymphomas.
Nature. 2009; 430: 694-649.
43. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM,
Romesser PB, et al. Chronic active B-cell-receptor signaling
in diffuse large B-cell lymphoma. Nature. 2010;
463: 88-92.
44. Honma K, Tsuzuki S, Nakagawa M, Tagawa H,
Nakamura S, Morishima Y, et al. TNFAIP3/A20 functions
as a novel tumor suppressor gene in several subtypes
of non-Hodgkin lymphomas. Blood. 2009; 114:
2467-2475.
45. Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI,
Hartmann S, Mechtersheimer G, et al. TNFAIP3 (A20)
is a tumor suppressor gene in Hodgkin lymphoma and
primary mediastinal B cell lymphoma. J Exp Med. 2009;
206: 981-989.
46. Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM,
Compagno M, et al. The NF-{kappa}B negative regulator
TNFAIP3 (A20) is inactivated by somatic mutations
and genomic deletions in marginal zone lymphomas.
Blood. 2009; 113: 4918-4921.
47. The International Non-Hodgkin’s Lymphoma Prognostic
Factors Project. A predictive model for aggressive non-
Hodgkin’s lymphoma. N Engl J Med. 1993; 329: 987-
994.
48. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K,
Hoskins P, et al. The revised International Prognostic
Index (R-IPI) is a better predictor of outcome than the
standard IPI for patients with diffuse large B-cell lymphoma
treated with R-CHOP. Blood. 2007; 109:
1857-1861.
49. Lerner RE, Thomas W, Defor TE, Weisdorf DJ, Burns
LJ. The International Prognostic Index assessed at
relapse predicts outcomes of autologous transplantation
for diffuse large-cell non-Hodgkin’s lymphoma in
second complete or partial remission. Biol Blood
Marrow Transplant. 2007; 13: 486-492.
50. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M,
Horsman DE, Tolcher AW, et al. Prognostic Significance
of Bcl-2 Protein Expression and Bcl-2 Gene
Rearrangement in Diffuse Aggressive Non-Hodgkin’s
Lymphoma. Blood. 1997; 90: 244-251.
51. Vitolo U, Gaidano G, Botto B, Volpe G, Audisio E, Bertini
M, et al. Rearrangements of bcl-6, bcl-2, c-myc and
6q deletion in B-diffuse large-cell lymphoma: Clinical
relevance in 71 patients. Ann Oncol. 1998; 9: 55-61.
52. Esteller M, Gaidano G, Goodman SN, Zagonel V,
Capello D, Botto B, et al. Hypermethylation of the DNA
Repair Gene O6-Methylguanine DNA Methyltransferase
and Survival of Patients With Diffuse Large B-Cell
Lymphoma. J Nat Cancer Ist. 2002; 94: 26-32.
53. Vitolo U, Botto B, Capello D, Vivenza D, Zagonel V,
Gloghini A, et al. Point mutations of the BCL-6 gene:
clinical and prognostic correlation in B-diffuse large cell
lymphoma. Leukemia. 2002; 16: 668-675.
54. Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R,
Sehn LH, et al. LMO2 protein expression predicts sur-
15